Role of Mitotane in Adrenocortical Carcinoma - Review and State of the art

Rosa Maria Paragliola, Francesco Torino, Giampaolo Papi, Pietro Locantore, Alfredo Pontecorvi, Salvatore Maria Corsello

Research output: Contribution to journalReview article

Abstract

Adrenocortical carcinoma (ACC) is a rare and aggressive endocrine tumour deriving from the adrenal cortex. A correct therapeutic strategy requires a multidisciplinary approach between endocrinologist, surgeon and oncologist. Surgery is the mainstay treatment in ACC while mitotane, deriving from the insecticide dichloro-diphenyl-trichloro-ethane, is the main base of the medical treatment of ACC in consideration of its adrenocytolitic activity. However, the use of mitotane as adjuvant therapy is still controversial, also in consideration of the retrospective nature of several studies. A prospective randomised trial (ADIUVO), recruiting patients with low-intermediate risk of recurrence, is evaluating the utility of adjuvant treatment with mitotane in this setting. The therapeutic response is observed with plasma levels of mitotane >14 mg/L. However, the major difficulty in the management of mitotane treatment is related to side effects and to the risk of toxicity, which is related to plasmatic levels >20 mg/L, that is considered the upper limit of the therapeutic window. Mitotane therapy results in adrenal insufficiency, and glucocorticoid replacement therapy has to be administered at higher doses than those used in other aetiologies of primary adrenal insufficiency. Furthermore, other endocrine side effects related to mitotane should be considered, in particular on thyroid hormone and testosterone metabolism. Waiting for new medical strategies on molecular targets, it will be mandatory to optimise the current knowledge by prospective trials and, in consideration of the rarity of the disease, collaborative studies between endocrinologists and oncologists are necessary.

Original languageEnglish
Pages (from-to)62-66
Number of pages5
JournalEuropean Endocrinology
Volume14
Issue number2
DOIs
Publication statusPublished - Sep 2018

Fingerprint

Mitotane
Adrenocortical Carcinoma
Therapeutics
Addison Disease
Adrenal Insufficiency
Ethane
Adrenal Cortex
Insecticides
Thyroid Hormones
Glucocorticoids
Testosterone

Cite this

Role of Mitotane in Adrenocortical Carcinoma - Review and State of the art. / Paragliola, Rosa Maria; Torino, Francesco; Papi, Giampaolo; Locantore, Pietro; Pontecorvi, Alfredo; Corsello, Salvatore Maria.

In: European Endocrinology, Vol. 14, No. 2, 09.2018, p. 62-66.

Research output: Contribution to journalReview article

Paragliola, RM, Torino, F, Papi, G, Locantore, P, Pontecorvi, A & Corsello, SM 2018, 'Role of Mitotane in Adrenocortical Carcinoma - Review and State of the art', European Endocrinology, vol. 14, no. 2, pp. 62-66. https://doi.org/10.17925/EE.2018.14.2.62
Paragliola, Rosa Maria ; Torino, Francesco ; Papi, Giampaolo ; Locantore, Pietro ; Pontecorvi, Alfredo ; Corsello, Salvatore Maria. / Role of Mitotane in Adrenocortical Carcinoma - Review and State of the art. In: European Endocrinology. 2018 ; Vol. 14, No. 2. pp. 62-66.
@article{d72b8b725db64ffe9ce5d084e126bb27,
title = "Role of Mitotane in Adrenocortical Carcinoma - Review and State of the art",
abstract = "Adrenocortical carcinoma (ACC) is a rare and aggressive endocrine tumour deriving from the adrenal cortex. A correct therapeutic strategy requires a multidisciplinary approach between endocrinologist, surgeon and oncologist. Surgery is the mainstay treatment in ACC while mitotane, deriving from the insecticide dichloro-diphenyl-trichloro-ethane, is the main base of the medical treatment of ACC in consideration of its adrenocytolitic activity. However, the use of mitotane as adjuvant therapy is still controversial, also in consideration of the retrospective nature of several studies. A prospective randomised trial (ADIUVO), recruiting patients with low-intermediate risk of recurrence, is evaluating the utility of adjuvant treatment with mitotane in this setting. The therapeutic response is observed with plasma levels of mitotane >14 mg/L. However, the major difficulty in the management of mitotane treatment is related to side effects and to the risk of toxicity, which is related to plasmatic levels >20 mg/L, that is considered the upper limit of the therapeutic window. Mitotane therapy results in adrenal insufficiency, and glucocorticoid replacement therapy has to be administered at higher doses than those used in other aetiologies of primary adrenal insufficiency. Furthermore, other endocrine side effects related to mitotane should be considered, in particular on thyroid hormone and testosterone metabolism. Waiting for new medical strategies on molecular targets, it will be mandatory to optimise the current knowledge by prospective trials and, in consideration of the rarity of the disease, collaborative studies between endocrinologists and oncologists are necessary.",
author = "Paragliola, {Rosa Maria} and Francesco Torino and Giampaolo Papi and Pietro Locantore and Alfredo Pontecorvi and Corsello, {Salvatore Maria}",
year = "2018",
month = "9",
doi = "10.17925/EE.2018.14.2.62",
language = "English",
volume = "14",
pages = "62--66",
journal = "European Endocrinology",
issn = "1758-3772",
publisher = "Touch Briefings",
number = "2",

}

TY - JOUR

T1 - Role of Mitotane in Adrenocortical Carcinoma - Review and State of the art

AU - Paragliola, Rosa Maria

AU - Torino, Francesco

AU - Papi, Giampaolo

AU - Locantore, Pietro

AU - Pontecorvi, Alfredo

AU - Corsello, Salvatore Maria

PY - 2018/9

Y1 - 2018/9

N2 - Adrenocortical carcinoma (ACC) is a rare and aggressive endocrine tumour deriving from the adrenal cortex. A correct therapeutic strategy requires a multidisciplinary approach between endocrinologist, surgeon and oncologist. Surgery is the mainstay treatment in ACC while mitotane, deriving from the insecticide dichloro-diphenyl-trichloro-ethane, is the main base of the medical treatment of ACC in consideration of its adrenocytolitic activity. However, the use of mitotane as adjuvant therapy is still controversial, also in consideration of the retrospective nature of several studies. A prospective randomised trial (ADIUVO), recruiting patients with low-intermediate risk of recurrence, is evaluating the utility of adjuvant treatment with mitotane in this setting. The therapeutic response is observed with plasma levels of mitotane >14 mg/L. However, the major difficulty in the management of mitotane treatment is related to side effects and to the risk of toxicity, which is related to plasmatic levels >20 mg/L, that is considered the upper limit of the therapeutic window. Mitotane therapy results in adrenal insufficiency, and glucocorticoid replacement therapy has to be administered at higher doses than those used in other aetiologies of primary adrenal insufficiency. Furthermore, other endocrine side effects related to mitotane should be considered, in particular on thyroid hormone and testosterone metabolism. Waiting for new medical strategies on molecular targets, it will be mandatory to optimise the current knowledge by prospective trials and, in consideration of the rarity of the disease, collaborative studies between endocrinologists and oncologists are necessary.

AB - Adrenocortical carcinoma (ACC) is a rare and aggressive endocrine tumour deriving from the adrenal cortex. A correct therapeutic strategy requires a multidisciplinary approach between endocrinologist, surgeon and oncologist. Surgery is the mainstay treatment in ACC while mitotane, deriving from the insecticide dichloro-diphenyl-trichloro-ethane, is the main base of the medical treatment of ACC in consideration of its adrenocytolitic activity. However, the use of mitotane as adjuvant therapy is still controversial, also in consideration of the retrospective nature of several studies. A prospective randomised trial (ADIUVO), recruiting patients with low-intermediate risk of recurrence, is evaluating the utility of adjuvant treatment with mitotane in this setting. The therapeutic response is observed with plasma levels of mitotane >14 mg/L. However, the major difficulty in the management of mitotane treatment is related to side effects and to the risk of toxicity, which is related to plasmatic levels >20 mg/L, that is considered the upper limit of the therapeutic window. Mitotane therapy results in adrenal insufficiency, and glucocorticoid replacement therapy has to be administered at higher doses than those used in other aetiologies of primary adrenal insufficiency. Furthermore, other endocrine side effects related to mitotane should be considered, in particular on thyroid hormone and testosterone metabolism. Waiting for new medical strategies on molecular targets, it will be mandatory to optimise the current knowledge by prospective trials and, in consideration of the rarity of the disease, collaborative studies between endocrinologists and oncologists are necessary.

U2 - 10.17925/EE.2018.14.2.62

DO - 10.17925/EE.2018.14.2.62

M3 - Review article

C2 - 30349596

VL - 14

SP - 62

EP - 66

JO - European Endocrinology

JF - European Endocrinology

SN - 1758-3772

IS - 2

ER -